Skip to content

Topical Cannabidiol Application and Skin Vascular Reactivity

Cannabidiol and Vascular Reactivity to Skin Sensory Nerve Stimulation

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05456113
Acronym
cannabidiol
Enrollment
0
Registered
2022-07-13
Start date
2024-12-01
Completion date
2026-10-01
Last updated
2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of Drug

Brief summary

Cannabidiol, or CBD, is an over-the-counter nutraceutical that is more commonly being used by healthy adults for pain management, recovery from strenuous exercise, and general wellness. However, little research exists on the effects of CBD in otherwise healthy individuals. This study uses iontophoresis, a common technique used in physical therapy, to determine the effectiveness of topical CBD in lessening the reflex increased cutaneous vascular conductance response to stimulation of the skin.

Interventions

BIOLOGICALCannabidiol

Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine

Sponsors

Penn State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men and women 18 years of age and older * English speaking * Non-obese class III, BMI ≤ 39.9 * Normal HbA1C of \<6.5%

Exclusion criteria

* Abnormal resting heart rate (\<60 or \>100 bpm) or BP (systolic \<100 or \>129 mmHg, diastolic \<60 or \>100 mmHg) values * Rash, skin disease, disorders of pigmentation * Known skin allergies * Diabetes * Nicotine use (e.g. smoking, chewing tobacco, vaping, etc.) * Illegal drug use * Recent (within the last 30 days) CBD users either topical or oral * Allergy or hypersensitivity to investigational agents * Women who are pregnant or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Cutaneous Vascular Conductance~5 hourspulse units as measured by laser Doppler flowmetry

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026